News
PRNAF
0.0009
NaN%
--
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN)
TipRanks · 5d ago
Alterity Flags Risks Around Forward‑Looking Corporate Outlook
TipRanks · 6d ago
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
TipRanks · 03/30 11:35
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Barchart · 03/30 06:25
Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan
TipRanks · 03/29 23:10
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
TipRanks · 03/26 07:51
Alterity Therapeutics Plans Issue of 150 Million Options on ASX
TipRanks · 03/19 06:17
Alterity Therapeutics Launches Facility to Sell Small Share Parcels
TipRanks · 03/12 02:43
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
Barchart · 03/09 06:25
Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
TipRanks · 03/09 00:52
Alterity Therapeutics Taps Vanderbilt Neurologist as Chief Medical Advisor Ahead of Phase 3 MSA Trial
TipRanks · 03/03 23:13
Alterity Therapeutics recognizes MSA Awareness Month
TipRanks · 03/02 12:29
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
Barchart · 03/02 06:25
Alterity Widens Half-Year Loss but Lifts Asset Backing on Higher Interest Income
TipRanks · 02/26 00:00
Alterity Therapeutics provides corporate update
TipRanks · 01/30 12:38
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 01/30 06:25
Alterity Sharpens ATH434 Phase 3 Plans as Phase 2 MSA Data Strengthen
TipRanks · 01/30 03:49
Alterity Therapeutics highlights key 2026 objectives
TipRanks · 01/21 12:36
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Barchart · 01/21 06:25
Alterity Therapeutics Advances Lead MSA Drug Toward Phase 3 After Strong Phase 2 Data
TipRanks · 01/21 00:08
More
Webull provides a variety of real-time PRNAF stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.